Bbc Inside Science

Prof Onur Boyman, Director of department of Immunology at University Hospital, Zurich, this week published a paper in the journal Nature Communications that presents a way of quantifying the risk of a Covid patient going on to develop Long Covid (or PACS as some call it) based on certain symptoms, but crucially also two key biomarkers in the blood. As he explains to Gaia, combining the levels in the blood of two key immunoglobulins (IgM and IgG3) with other pointers, first identified last year, allowed him and his team to make successful predictions as to the relative likelihood his sample group of patients might go on to still be exhibiting symptoms beyond four weeks after infection. Asthma is of particular interest to these researchers, partly because it can share this blood signal of Ig markers. Might it even also shed any light on things such as Chronic Fatigue Syndrome?Dr Claire Steves, of Kings College London, whose previous work on symptom gathering Onur's team have built upon, agrees this is a promisi